NJBIZ Editor Jeff Kanige Interviews HINJ President and Chief Executive Officer Dean Paranicas About the Battle of NJ Life Science’s Companies During the COVID-19 Pandemic
The Health Care Institute of New Jersey counts among its members some of the world’s most prominent life sciences companies. This concentration of expertise and capabilities puts the state on the front lines of the fight against the COVID-19 pandemic. NJBIZ Editor Jeff Kanige recently spoke about the battle with HINJ President and Chief Executive […]
Leading State Life Sciences Associations Express Concerns with CMS VBP Rule
BioNJ, Biocom, the California Life Sciences Association (CLSA), the Healthcare Institute of New Jersey (HINJ), Life Sciences Pennsylvania (LSPA), and the Michigan Biosciences Industry Association (MichBio) today sent comments to the Centers for Medicare and Medicaid Services (CMS) on a notice of proposed rulemaking (NPRM) on value-based purchasing (VBP) and other issues. While commending CMS […]
HealthCare Institute of New Jersey Hires New Director of Communications
New Brunswick, June 23, 2020 ― The HealthCare Institute of New Jersey (HINJ) has announced the hiring of Allison Freeman as its new Director of Communications, effective June 16, 2020. Mrs. Freeman was a long-time reporter for The Star-Ledger, covering general assignment news, Essex County news, government, health, education, the arts, and entertainment. She has […]
HealthCare Institute of New Jersey Announces New Board and Steering Committee Leadership
The HealthCare Institute of New Jersey (HINJ) has announced new officers of its Board of Trustees and the leadership of its Steering Committee, effective May 26. Jack Cox, Senior Director, Market Access Strategy, Novo Nordisk, has been elected Chair of the HINJ Board of Trustees. He previously served as Treasurer. Mr. Cox has over thirty […]
Rep. Gottheimer Honored by HINJ for Patient Access and Advocacy
The HealthCare Institute of New Jersey (HINJ) today (March 6) honored U.S. Congressman Josh Gottheimer (NJ-5) with the 2020 HINJ Recognition Award for Patient Access and Advocacy. “Congressman Gottheimer is a leader in protecting the patient community by encouraging the research and development of new medicines and medical technologies, particularly for those disease states that […]
CEOs of two HINJ-member companies and HINJ CEO named to 2020 NJBIZ Power 100
Kenneth Frazier, chairman and chief executive officer of Merck; Alex Gorsky, chairman and chief executive officer of Johnson & Johnson; and Dean J. Paranicas, president and chief executive officer of HINJ, have been named to the 2020 NJBIZ Power 100 list released Feb. 18. Please read more here.
Innovation state (ROI-NJ): Paranicas explains how life sciences, tech firms are advancing health care
Dean Paranicas, CEO and president of the HealthCare Institute of New Jersey, isn’t just another state trade organization leader. Given that at least 11 of the Top 20 medical technology companies have a presence in New Jersey, representing them — as the HealthCare Institute of New Jersey does — means giving a voice to a big […]
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
A new report from TEConomy Partners found that the biopharmaceutical industry supports over four million U.S. jobs and over $1.1 trillion in economic output. The biopharmaceutical industry directly employs more than 811,000 people in our country, and each of those jobs supports four additional jobs in other industries. Of the direct industry jobs, 37% are in […]
Almost Half of Spending on Brand Medicines Goes to PBMs, the Supply Chain, Other Entities – Not to Drug Companies
$166 billion in discounts intended for patients goes to middlemen New Brunswick, Jan. 29, 2020 ― An important new study sheds light on the dynamics of drug pricing, finding that almost half of spending on brand medicines in the United States goes to pharmacy benefit managers (PBMs), hospitals, health insurers, the government and others – […]
We can lower health care costs and keep N.J.’s pharmaceutical industry hard at work at the same time (NJ.com)
Although New Jersey’s biopharmaceutical sector opposed H.R. 3, we share its overriding goal – to ensure that patients can access the treatments and cures that these companies work so hard to discover. While many provisions in H.R. 3 wouldn’t actually lower costs for patients, we will continue seeking comprehensive, realistic ways to lower costs for […]